ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/androgen-axis
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/androgen-axis
44
trial(s) found.
NCT07336446
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Metastatic Prostate Cancer (
ANDROMEDA
)
AR PROTAC degrader
+ endocrine therapy,androgen axis-targeting
Prostate cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT07277270
Advanced
Phase 1
Recruiting
A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
anti-B7H3 antibody-drug conjugate
+ endocrine therapy,androgen axis-targeting
Cancer
QLD
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
NCT07226986
Radonc
Phase 1 / Phase 2
Recruiting
A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) (
CAMO959A12103
)
radioconjugate,PSMA-targeting
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07213674
Advanced
Phase 3
Recruiting
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
CYP17A1 inhibitor
bispecific T-cell engager,STEAP1-targeting
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3168 - Clayton - Monash Medical Centre
QLD
4029 - Herston - Icon Cancer Care Wesley
NCT07206056
Advanced
Phase 1 / Phase 2
Recruiting
TulmiSTAR-01
: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
AR PROTAC degrader
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
NCT07140900
Advanced
Phase 1
Recruiting
A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
bispecific T-cell engager,STEAP1-targeting
+ endocrine therapy,androgen axis-targeting
Castrate-sensitive prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
NCT07047118
Advanced
Phase 2
Recruiting
A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Lutetium (177Lu) Vipivotide Tetraxetan in Adult Male Patients With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) (
CJSB462B12201
)
AR PROTAC degrader
radioconjugate,PSMA-targeting
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT07028853
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Mevrometostat (PF-06821497) With Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (MEVPRO-3) (
C2321008
)
EZH2 inhibitor
antiandrogen,nonsteroidal,second generation
placebo
+ endocrine therapy,androgen axis-targeting
Cancer
Castrate-sensitive prostate cancer
Prostate cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
QLD
4032 - Chermside - Icon Cancer Care Chermside
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NZ
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NCT06991556
Advanced
Phase 2
Recruiting
A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) (
CJSB462C12201
)
AR PROTAC degrader
CYP17A1 inhibitor
+ endocrine therapy,androgen axis-targeting
Castrate-sensitive prostate cancer
VIC
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06952803
Curative
Phase 3
Recruiting
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02). (
EvoPAR-PR02
)
PARP1-selective inhibitor
placebo
radiotherapy
+ endocrine therapy,androgen axis-targeting
Prostate cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (WITHDRAWN)
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06863272
Advanced
Phase 1 / Phase 2
Recruiting
MK-
2400-01A
Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)
anti-B7H3 antibody-drug conjugate
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06855277
Radonc
Phase 3
Recruiting
A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (
AcTFirst
)
radioligand,PSMA-targeting
+ endocrine therapy,androgen axis-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06830850
Advanced
Phase 1
Recruiting
A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer (
HRS-5041-103
)
AR PROTAC degrader
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT06764485
Advanced
Phase 3
Recruiting
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) -
rechARge
dual AR degrader antagonist
taxane
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2560 - Campbelltown - GenesisCare Campbelltown
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06691984
Advanced
Phase 3
Recruiting
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy
bispecific T-cell engager,STEAP1-targeting
taxane
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06629779
Advanced
Phase 3
Recruiting
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2) (
C2321003
)
EZH2 inhibitor
antiandrogen,nonsteroidal,second generation
placebo
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.3210 - Hamilton - Waikato Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06594926
Curative
Phase 2
Recruiting
Evaluating the Efficacy of Bipolar Androgen Therapy in Extending Metastasis-free Survival in Patients With M0 Castrate-resistant Prostate Cancer With PSA Progression But Not Radiological or Clinical Progression on Darolutamide (
WOMBAT
)
antiandrogen,nonsteroidal,second generation
+ endocrine therapy,androgen axis-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2640 - Albury - Border Medical Oncology Research Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3677 - Wangaratta - Northeast Health Wangaratta
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06551324
Advanced
Phase 3
Recruiting
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (
MEVPRO-1
)
CYP17A1 inhibitor
EZH2 inhibitor
antiandrogen,nonsteroidal,second generation
taxane
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT06520345
Radonc
Phase 3
Recruiting
A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment (
177Lu-TLX591-203
)
177Lu-anti-PSMA-radioconjugate
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3051 - Melbourne - Australian Prostate Centre
WA
6150 - Murdoch - GenesisCare Murdoch
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06353386
Advanced
Phase 1 / Phase 2
Recruiting
MK-
5684-01A
Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
CYP11A1 inhibitor
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06136650
Advanced
Phase 3
Recruiting
MK-
5684-004
: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)
CYP11A1 inhibitor
CYP17A1 inhibitor
antiandrogen,nonsteroidal,second generation
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
Prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.9016 - Dunedin - Dunedin Hospital (COMPLETED)
NCT06136624
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (
OMAHA-003
)
CYP11A1 inhibitor
CYP17A1 inhibitor
antiandrogen,nonsteroidal,second generation
+ endocrine therapy,androgen axis-targeting
Prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2830 - Dubbo - Dubbo Base Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NZ
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.9016 - Dunedin - Dunedin Hospital
NCT06120491
Advanced
Phase 3
Recruiting
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) (
EvoPAR-PR01
)
PARP1-selective inhibitor
placebo
+ endocrine therapy,androgen axis-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (TERMINATED)
2031 - Randwick - Prince of Wales Hospital (WITHDRAWN)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5037 - Glandore - Ashford Cancer Centre
NCT05997615
Advanced
Phase 1
Recruiting
A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Participants With Prostate Cancer (
VIR-5500-V101
)
unknown drug class
+ endocrine therapy,androgen axis-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05914116
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors (
DB-1311-O-1001
)
anti-B7H3 antibody-drug conjugate
+ endocrine therapy,androgen axis-targeting
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2228 - Miranda - Southside Cancer Care Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - John Hunter Children's Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05827081
Curative
Phase 3
Recruiting
A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) (
Adjuvant-WIDER
)
CDK4/6 inhibitor
+ endocrine therapy,androgen axis-targeting
Breast cancer
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3168 - Clayton - Monash Medical Centre
NCT05818683
Advanced
Phase 1
Recruiting
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer (
CR109321
)
anti-PD-1 monoclonal antibody
bispecific T-cell engager,KLK2-targeting
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
Castrate-sensitive prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT05800665
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer (
GO44537
)
AR PROTAC degrader
unknown drug class
+ endocrine therapy,androgen axis-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
NCT05519449
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (
PSMA-007-001
)
PSMA-tumor-activated T-cell engager
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
Prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05413421
Advanced
Phase 1
Recruiting
An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer (
ORIC-944-01
)
PRC2 complex inhibitor
+ endocrine therapy,androgen axis-targeting
Prostate cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
NCT05393791
Advanced
Phase 2
Recruiting
ANZadapt
: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer
CYP17A1 inhibitor
antiandrogen,nonsteroidal,second generation
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT04947189
Advanced
Phase 1 / Phase 2
Recruiting
4CAST
: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer
CYP17A1 inhibitor
+ endocrine therapy,androgen axis-targeting
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
NCT04925648
Advanced
Phase 2
Recruiting
PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction (
PICASSO
)
AR-targeted agent,next generation
AR-targeted agent,second generation
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
Darolutamide
Dasatinib
KIT inhibitor
PDGFRA inhibitor
SRC inhibitor
YES1 inhibitor
antiandrogen
antiandrogen,nonsteroidal
antiandrogen,nonsteroidal,second generation
cancer therapy
cancer therapy,AR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,SRC-targeting
cancer therapy,YES1-targeting
endocrine therapy
endocrine therapy,androgen axis-targeting
+ endocrine therapy,androgen axis-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04597411
Radonc
Phase 1
Recruiting
AcTION: A Phase I Study of [225Ac]Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer With or Without Prior [177Lu]Lu-PSMA-617 Radioligand Therapy (
PSMA-617-100
)
radioligand,PSMA-targeting
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
NCT04464226
Advanced
Phase 3
Recruiting
An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies
antiandrogen,nonsteroidal,second generation
+ endocrine therapy,androgen axis-targeting
Cancer
SA
5037 - Glandore - Ashford Cancer Centre (COMPLETED)
NCT04221542
Advanced
Phase 1
Recruiting
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
bispecific T-cell engager,STEAP1-targeting
+ endocrine therapy,androgen axis-targeting
Prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
NCT02960022
Advanced
Phase 2
Recruiting
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study (
9785-CL-0123
)
antiandrogen,nonsteroidal,second generation
+ endocrine therapy,androgen axis-targeting
Prostate cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2076 - Wahroonga - Sydney Adventist Hospital (COMPLETED)
2485 - Tweed Heads - The Tweed Hospital (COMPLETED)
2640 - Albury - Border Medical Oncology Research Unit (COMPLETED)
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (COMPLETED)
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (COMPLETED)
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)
SA
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT02861573
Advanced
Phase 1 / Phase 2
Recruiting
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (
KEYNOTE-365
)
anti-PD-1 monoclonal antibody
+ endocrine therapy,androgen axis-targeting
Castrate-resistant prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12625000224426
Radonc
Not Applicable
Not yet recruiting
Salvage sTereotactic Ablative radiotherapy for patients with Recurrent prostate cancer With Androgen suppression and Rectal Spacer, assessing toxicity and quality of life (
STARWARS
)
radiotherapy
+ endocrine therapy,androgen axis-targeting
Prostate cancer
VIC
3004 - Melbourne, Southbank - Alfred Health
3844 - Traralgon - Latrobe Regional Hospital
ACTRN12624001458527
Advanced
Phase 2
Not yet recruiting
Randomised Phase 2 study of sphingosine kinase inhibitor (opaganib) in addition to darolutamide in people with poor prognostic metastatic castration resistant prostate cancer (mCRPC) based on a companion circulating lipid biomarker, PCPro (ANZUP2205) (
DARO-LIPID
)
antiandrogen,nonsteroidal,second generation
sphingosine kinase-2 inhibitor
+ endocrine therapy,androgen axis-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2830 - Dubbo - Dubbo Base Hospital
VIC
3630 - Shepparton - Goulburn Valley Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12624000582550
Curative
Phase 2
Recruiting
Evaluating the efficacy of bipolar androgen therapy in extending metastasis-free survival in patients with M0 castrate-resistant prostate cancer with prostate specific antigen progression but not radiological or clinical progression on darolutamide (
WOMBAT
) - ANZUP 2201
antiandrogen,nonsteroidal,second generation
+ endocrine therapy,androgen axis-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12624000110583
Advanced
Not Applicable
Recruiting
SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies (
SOCRATES-PILOT
)
AR-targeted agent,next generation
AR-targeted agent,second generation
Abiraterone
Anastrozole
Apalutamide
Atorvastatin
Bevacizumab
CYP17A1 inhibitor
Darolutamide
Enzalutamide
HMG-CoA reductase inhibitor
Letrozole
Lomustine
Nab-paclitaxel
Niraparib
Olaparib
PARP inhibitor
Paclitaxel
alkylating agent
anti-VEGF monoclonal antibody
antiandrogen
antiandrogen,nonsteroidal
antiandrogen,nonsteroidal,second generation
aromatase inhibitor
cancer therapy
cancer therapy,AR-targeting
cancer therapy,CYP17A1-targeting
cancer therapy,HMG-CoA reductase-targeting
cancer therapy,PARP-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,androgen axis-targeting
endocrine therapy,oestrogen axis-targeting
immuno-oncology therapy,VEGF-targeting
oestrogen receptor-targeting therapy
taxane
+ endocrine therapy,androgen axis-targeting
Cervical cancer
Glioblastoma
Ovarian cancer
Prostate cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
ACTRN12623000160639
Curative
Phase 2
Not yet recruiting
A Randomized, Open-Label, Phase 2 Study of Darolutamide as Single Agent or in Combination with EPI-7386 as a Neoadjuvant Treatment for Patients Undergoing Prostatectomy for Localized Prostate Cancer (
DaSCENT
)
antiandrogen,AR NTD inhibitor
antiandrogen,nonsteroidal,second generation
+ endocrine therapy,androgen axis-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
NCT04122976
Curative
Active not recruiting
Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients (
DAROL
)
antiandrogen,nonsteroidal,second generation
+ endocrine therapy,androgen axis-targeting
Prostate cancer
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (39)
Not yet recruiting (4)
Active not recruiting (1)
Recruitment Country and State
NSW (34)
VIC (26)
QLD (18)
SA (13)
WA (10)
NZ (9)
TAS (1)
ACT (1)
NT (1)
Phase
Phase 1 (10)
Phase 1 / Phase 2 (8)
Phase 2 (9)
Phase 3 (14)
Trial Type
Advanced (33)
Curative (6)
Radonc (5)
Cancer Therapy Class
androgen axis
100%
AR
86%
CYP17A1
55%
PARP
14%
oestrogen axis
14%
PSMA
11%
STEAP1
9%
CYP11A1
9%
PARP1-selective
7%
B7H3
7%
VEGF
7%
EZH2
7%
GnRH
7%
LHRH
5%
PD-1
5%
PD-1/PD-L1
5%
SMO
2%
CDK4
2%
CDK6
2%
KLK2
2%
PRC2 complex
2%
BCR-ABL1
2%
KIT
2%
PDGFRA
2%
SRC
2%
YES1
2%
HIF2a
2%
TIGIT
2%
sphingosine kinase-2
2%
HMG-CoA reductase
2%
antiandrogen,AR NTD
2%
Facility
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (13)
3000 - Melbourne - Peter MacCallum Cancer Centre (11)
2109 - North Ryde - Macquarie University Hospital (11)
3168 - Clayton - Monash Medical Centre (8)
2050 - Camperdown - Chris O'Brien Lifehouse (8)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (8)
2076 - Wahroonga - Sydney Adventist Hospital (8)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (7)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (6)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (6)
4102 - Woolloongabba - Princess Alexandra Hospital (6)
6150 - Murdoch - Fiona Stanley Hospital (5)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (5)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
3004 - Melbourne, Southbank - Alfred Health (4)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (4)
3128 - Box Hill - Box Hill Hospital - Eastern Health (4)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (4)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (3)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (3)
2065 - St Leonards - GenesisCare North Shore Private Hospital (3)
2640 - Albury - Border Medical Oncology Research Unit (3)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (3)
NZ.9016 - Dunedin - Dunedin Hospital (3)
4032 - Chermside - Icon Cancer Care Chermside (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (2)
2500 - Wollongong - Wollongong Hospital (2)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (2)
6009 - Nedlands - Linear Clinical Research (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
4120 - Greenslopes - Greenslopes Private Hospital (2)
NZ.3210 - Hamilton - Waikato Hospital (2)
2830 - Dubbo - Dubbo Base Hospital (2)
2031 - Randwick - Prince of Wales Hospital (2)
4032 - Chermside - The Prince Charles Hospital (2)
5037 - Glandore - Ashford Cancer Centre (2)
2139 - Concord - Concord Repatriation General Hospital (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
4029 - Herston - Icon Cancer Care Wesley (1)
2170 - Liverpool - Liverpool Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2560 - Campbelltown - GenesisCare Campbelltown (1)
4215 - Southport - Tasman Oncology (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2605 - Garran - The Canberra Hospital (1)
3677 - Wangaratta - Northeast Health Wangaratta (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
3051 - Melbourne - Australian Prostate Centre (1)
6150 - Murdoch - GenesisCare Murdoch (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2228 - Miranda - Southside Cancer Care Centre (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
2217 - Kogarah - St George Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
2485 - Tweed Heads - The Tweed Hospital (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (1)
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
3630 - Shepparton - Goulburn Valley Health (1)
Cancer Type
Cancer
Solid tumour
Male genital cancers
Prostate cancer
Urogenital cancer
Prostate adenocarcinoma
Castrate-resistant prostate cancer
Castrate-sensitive prostate cancer
Breast cancer
Breast adenocarcinoma
Triple-negative breast cancer
Central nervous system cancer
Cervical cancer
Glioblastoma
Glioma
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
High-grade glioma
Malignant glioma
Neurological cancer
Ovarian cancer
Viral-related cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy